We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

Edwards SAPIEN XT Transcatheter Heart Valve ... the quality of life in patients who otherwise have limited choices for repair of their aortic valve. The TAVR procedure is not right for everyone. In ...

Edwards is focused on positioning TAVR for long-term growth ... those who received Edwards’ newest generation SAPIEN 3 Ultra RESILIA valve have experienced outstanding one-year outcomes.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Eligible patients were randomized to receive the second-generation Edwards SAPIEN heart-valve system or usual care. Patients randomized to TAVR group received heparin therapy during the procedure ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

California-based Edwards (NYSE:EW) its only sell-equivalent rating on Wall Street amid 14 buy-equivalent ratings. Citing an FDA dataset from the company's Partner 3 trial for its TAVR heart valve ...

Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter ...

The first human TAVR was performed by Dr. Cribier in 2002. [33] There have been three generations of the Cribier-Edwards SAPIEN valve. The only valve that has FDA approval is the Edwards SAPIEN ...